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KEY POINTS 
• Thrombomodulin (TM)-associated coagulopathy is a heritable bleeding 
disorder in which high plasma TM levels reduce thrombin generation 
 
• High plasma TM levels also delay clot lysis by enhancing TM/thrombin-
mediated activation of thrombin activatable fibrinolysis inhibitor 
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ABSTRACT 
Thrombomodulin-associated coagulopathy (TM-AC) is a newly recognised 
dominant bleeding disorder in which a p.Cys537Stop variant in the 
thrombomodulin (TM) gene THBD, results in high plasma TM levels and 
protein C-mediated suppression of thrombin generation. Thrombin in complex 
with TM also activates thrombin activatable fibrinolysis inhibitor (TAFI). 
However, the effect of the high plasma TM on fibrinolysis in TM-AC is 
unknown. Plasma from TM-AC cases and high-TM model control samples 
spiked with recombinant soluble TM showed reduced tissue factor-induced 
thrombin generation. Lysis of plasma clots from TM-AC cases was 
significantly delayed compared to controls, but was completely restored when 
TM/thrombin-mediated TAFI activation was inhibited. Clots formed in blood 
from TM-AC cases had the same viscoelastic strength as controls but also 
showed a TAFI-dependent delay in fibrinolysis. Delayed fibrinolysis was 
reproduced in high-TM model plasma and blood samples. Partial restoration 
of thrombin generation with rFVIIa or aPCC did not alter the delayed 
fibrinolysis in high-TM model blood. Our finding of a previously unrecognised 
fibrinolytic phenotype indicates that bleeding in TM-AC has a complex 
pathogenesis and highlights the pivotal role of TM as a regulator of 
haemostasis.  
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INTRODUCTION 
Thrombomodulin (TM) is a type-1 transmembrane glycoprotein encoded by 
THBD and expressed at high levels on vascular endothelial cells1. TM binds 
thrombin with high affinity and changes its substrate specificity to favour 
protein C (PC), which when activated to APC down-regulates further thrombin 
generation by inactivating factors Va and VIIIa2,3. Consistent with this down-
regulatory role, reduced endothelial TM expression has been associated with 
disseminated intravascular coagulation4 and venous thrombosis5. TM has 
also been linked to the pathogenesis of a dominant bleeding disorder caused 
by a THBD variant predicting a p.Cys537Stop substitution in the TM 
transmembrane domain. This results in high plasma TM levels, consistent 
with shedding of TM extracellular domain from the endothelium6,7. It has been 
proposed that abnormal bleeding in this disorder, hereafter termed TM-
associated coagulopathy (TM-AC), results from enhanced TM-mediated APC 
generation and suppression of further thrombin generation6,7. 
 
In addition to mediating APC generation, TM in complex with thrombin is also 
a potent activator of thrombin-activatable fibrinolysis inhibitor (TAFI)8. 
Activated TAFI (TAFIa) cleaves carboxyl-terminal lysine residues from the 
fibrin surface thereby reducing binding of plasminogen and tPA, and down-
regulating fibrinolysis9 ,10. Here we describe the impact of high plasma TM 
levels on TAFI-mediated clot lysis in an unreported pedigree with TM-AC and 
reveal a previously unrecognised fibrinolytic component of the TM-AC 
phenotype.  
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METHODS 
Study cases and coagulation studies  
The study cases were enrolled to the NIHR BioResource rare diseases (UK 
REC 13/EE/0325) after informed written consent, in accordance with the 
Declaration of Helsinki. Plasma TM concentration was measured by ELISA 
(Abcam, Cambridge, UK). Calibrated automated thrombography (CAT) was 
performed on platelet poor plasma with the PPP LOW reagent (1 pM tissue 
factor (TF) and a Fluoroscan fluorimeter (Thermo-Fisher, Basingstoke, UK)11. 
Experiments were also performed in high-TM model blood or plasma using 
samples from healthy controls spiked with 250-2500 ng/ml recombinant C-
terminal truncated TM (Peprotech, Hamburg, Germany). THBD was analysed 
by whole genome sequencing through the BRIDGE-BPD project12 and the 
ThromboGenomics high-throughput platform13. 
 
Plasma fibrinolysis  
Clots were formed in re-calcified, diluted plasma with 0.1 U/ml thrombin 
(Sigma-Aldrich, Poole, UK) as previously reported14 in the presence of 300 
pM recombinant tissue plasminogen activator (tPA; Genentech, San 
Francisco, Ca) and 16 µM phospholipids (Rossix, Molndal, Sweden). Clots 
were formed in the absence or presence of 500 ng/ml TM, 25 µg/ml potato 
tuber carboxypeptidase inhibitor (PTCI; Sigma-Aldrich; a TAFIa inhibitor) or 
65 µg/ml MA-T12D11 (a monoclonal antibody inhibitor of thrombin/TM-
mediated TAFI activation15). Turbidity was monitored every minute at 405 nm.  
 
Whole blood fibrinolysis 
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Clots were formed in re-calcified whole blood samples containing 210 pM tPA 
(Genentech) using the EXTEM reagent and monitored by rotational 
thromboelastometry (ROTEM®, Tem International GmbH, Munchen, 
Germany), in the presence or absence of 1-10 µg/ml PTCI, 25-100 µg/mL 
recombinant activated FVII (rFVIIa; NovoNordisk, Bagsværd, Denmark) or 
0.25-0.75 U/mL activated prothrombin complex concentrate (aPCC; Baxalta, 
Bannockburn, IL). Data are expressed as means ± SEM and were analysed 
by two way ANOVA with Dunnett’s post hoc test. 
 
RESULTS and DISCUSSION 
The study cases were males aged 59 and 34 years (I.1 and II.2; Figure 1A) 
with a lifelong propensity for muscle and joint bleeding after minor trauma. 
Treatment of bleeding with plasma or Factor IX infusions was ineffective. 
However, single 90 µg/Kg infusions of rFVIIa (NovoNordisk) were usually 
sufficient to resolve bleeding. Analysis of plasma by CAT showed that 
compared to healthy controls, the cases had reduced endogenous thrombin 
potential (ETP; 316.3 ± 51.5 nM/min (n=10) vs 1584.9 ± 56.2 nM/min in 
controls (n=20); P<0.01) and reduced peak thrombin concentration (71.7 ± 
12.5 nM (n=10) vs 273.7 ± 19.6 nM in controls (n=20); P<0.01; Figure 1B, C). 
Cases and controls showed similar lag time and time to peak thrombin. The 
plasma TM concentration in the cases was 640.7 ± 21.2 ng/ml (n=4; reference 
interval 2.9-7.6 ng/ml). No other abnormalities were observed in coagulation 
factor or anticoagulant protein levels (Supplementary Table S1).  
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Consistent with this phenotype, both cases had heterozygous c.1611C>A 
transversions in the major THBD transcript NM_000361.2 which segregated in 
the pedigree with abnormal bleeding. This predicted p.Cys537Stop in the TM 
transmembrane domain, an identical variant to the two previously reported 
TM-AC pedigrees (Figure 1A)6,7. Addition of sTM to control plasma caused 
dose dependent reductions in ETP and peak thrombin, that with 500 ng/ml 
sTM were similar to the cases (Figure 1C, D). This indicated a causal 
relationship between high plasma TM levels in the TM-AC cases and reduced 
thrombin generation. Addition of the bypassing agents rFVIIa or aPCC, which 
enhance thrombin generation in other coagulopathies, increased ETP in high-
TM model plasma, similar to that in pooled FVIII-deficient control plasma 
samples (P<0.01 for ETP with 2-100 µg/ml rFVIIa or 0.25-0.75 U/ml aPCC vs 
ETP with no bypassing agent). Restoration of ETP was less than in the TM-
AC plasmas (P<0.01 for ETP with 50-100 µg/ml rFVIIa or 0.5-0.75 U/ml aPCC 
vs ETP with no bypassing agent; Figure 1E, F). 
 
Fibrinolysis phenotype 
Lysis of TM-AC plasma clots by tPA was significantly slower than controls 
(time to 50% lysis 175.1 ± 3.4 min (n=6) vs 103.1 ± 3.9 min in controls (n=3); 
P<0.01), and was reproduced in high-TM model plasma (time to 50% lysis 
164.1 ± 8.6 min (n=3); P<0.01; Figure 2A, D). Addition of MA-T12D11, which 
specifically inhibits thrombin/TM-mediated TAFI activation15, completely 
abrogated delayed fibrinolysis in the TM-AC and high-TM model plasma 
samples (Figure 2B, D). Similarly, inclusion of the TAFIa inhibitor PTCI (25 
µg/ml) also reduced the delay in fibrinolysis in TM-AC plasma, although did 
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not completely reduce the 50% lysis time in the high-TM model to control 
levels (Figure 2C, D).  
 
Clots formed in TM-AC and high-TM model blood samples showed the same 
maximum clot firmness as controls (Figure 2E and Supplementary table 
S1), indicating no differences in initial clot viscoelastic strength. However 
compared to controls, the time to 90% lysis was significantly delayed in TM-
AC blood (time to 90% lysis 56.5 ± 2.3 min (n=7) vs 29.5 ± 3.5 min in controls 
(n=3); P<0.01) and in high-TM model blood (50.4 ± 2.0 (n=3); P<0.01; Figure 
2E, F), indicating delayed fibrinolysis. Addition of PTCI 1-10 µg/ml caused a 
dose-dependent reduction in the delay in fibrinolysis in TM-AC and high-TM 
model blood samples (Figure 2E, F), reproducing the effects in plasma. 
Addition of 25-100 ng/ml rFVIIa or 0.25-0.75 U/ml aPCC, which partially 
restored thrombin generation in TM-AC and high-TM model samples, did not 
alter the delayed fibrinolysis in high TM-model blood (Figure 2G). 
 
We confirm that TM-AC is associated with reduced thrombin generation and 
reveal that delayed fibrinolysis is a component of the TM-AC phenotype using 
two experimental models. We show further that both phenotypes are a 
consequence of high plasma TM levels and that the delay in fibrinolysis is 
TAFIa-mediated, in line with the established role of TM/thrombin in TAFI 
activation9 ,10. It is significant that in the presence of high TM levels, enhanced 
TAFI activation occurred despite reduced thrombin generation and that partial 
restoration of thrombin generation with rFVIIa or aPCC did not alter the 
delayed fibrinolysis. This suggests that in TM-AC, TM rather than thrombin is 
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the main determinant of TAFI activation. Our findings highlight the complex 
multifactorial role of TM in the regulation of haemostasis and have important 
implications for the treatment of bleeding in TM-AC. 
 
ACKNOWLEDGEMENTS 
The NIHR BioResource-Rare Diseases and the ThromboGenomics 
sequencing projects are supported by the National Institute for Health 
Research (NIHR; http://www.nihr.ac.uk). KB is an NIHR academic clinical 
fellow. SKW is supported by a Medical Research Council (MRC) Clinical 
Training Fellowship (MR/K023489/1). KS and ET are supported by the NIHR 
BioResource Rare Diseases. CSW and NJM are supported by the British 
Heart Foundation (FS/11/2/28579). ADM is supported by the NIHR Bristol 
Cardiovascular Biomedical Research Unit.  
 
AUTHORSHIP CONTRIBUTIONS 
KB performed experiments and co-wrote the manuscript. CSW, MW, CRS 
and PC performed experiments. SKW and OGC enrolled the study cases and 
provided the phenotype descriptions. KS and ET designed and performed 
genetic analyses. NJM designed experiments and co-wrote the manuscript. 
ADM oversaw the study, designed experiments and co-wrote the manuscript.  
We thank Prof Paul Declerck and Prof Ann Gils, University Leuven, Belgium 
for the kind gift of the MA-T12D11 antibody to TAFI.    
 
DISCLOSURE OF CONFLICTS OF INTEREST 
The authors declare no relevant conflicts of interest 
 10 
REFERENCES 
1. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost. 
2003;1(7):1515-1524. 
2. Adams TE, Huntington JA. Thrombin-cofactor interactions: structural 
insights into regulatory mechanisms. Arterioscler Thromb Vasc Biol. 
2006;26(8):1738-1745. 
3. Griffin JH, Zlokovic BV, Mosnier LO. Protein C anticoagulant and 
cytoprotective pathways. Int J Hematol. 2012;95(4):333-345. 
4. Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. 
Recombinant human soluble thrombomodulin in severe sepsis: a systematic 
review and meta-analysis. J Thromb Haemost. 2015;13(4):508-519. 
5. Hernandez W, Gamazon ER, Smithberger E, et al. Novel genetic 
predictors of venous thromboembolism risk in African Americans. Blood. 
2016;127(15):1923-1929. 
6. Langdown J, Luddington RJ, Huntington JA, Baglin TP. A hereditary 
bleeding disorder resulting from a premature stop codon in thrombomodulin 
(p.Cys537Stop). Blood. 2014;124(12):1951-1956. 
7. Dargaud Y, Scoazec JY, Wielders SJ, et al. Characterization of an 
autosomal dominant bleeding disorder caused by a thrombomodulin mutation. 
Blood. 2015;125(9):1497-1501. 
8. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase 
B, couples the coagulation and fibrinolytic cascades through the thrombin-
thrombomodulin complex. J Biol Chem. 1996;271(28):16603-16608. 
 11 
9. Bajzar L, Nesheim M, Morser J, Tracy PB. Both cellular and soluble 
forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of 
thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273(5):2792-2798. 
10. Binette TM, Taylor FB, Jr., Peer G, Bajzar L. Thrombin-
thrombomodulin connects coagulation and fibrinolysis: more than an in vitro 
phenomenon. Blood. 2007;110(9):3168-3175. 
11. Dargaud Y, Wolberg AS, Luddington R, et al. Evaluation of a 
standardized protocol for thrombin generation measurement using the 
calibrated automated thrombogram: an international multicentre study. 
Thromb Res. 2012;130(6):929-934. 
12. Westbury SK, Turro E, Greene D, et al. Human phenotype ontology 
annotation and cluster analysis to unravel genetic defects in 707 cases with 
unexplained bleeding and platelet disorders. Genome Med. 2015;7(1):36. 
13. Simeoni I, Stephens JC, Hu F, et al. A comprehensive high-throughput 
sequencing test for the diagnosis of inherited bleeding, thrombotic and platelet 
disorders. Blood. 2016; 127(23): 2791-2803. 
14. Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, 
scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost. 
2003;1(9):2000-2007. 
15. Develter J, Booth NA, Declerck PJ, Gils A. Bispecific targeting of 
thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 
by a heterodimer diabody. J Thromb Haemost. 2008;6(11):1884-1891. 
 
 
 
 12 
FIGURE LEGENDS 
Figure 1: Reduced thrombin generation in the study cases and response 
to rFVIIa and aPCC. 
A. Pedigree of the study cases with traumatic bleeding indicated by the solid 
symbols and no abnormal bleeding by open symbols. Genotyped cases are 
indicated as +/V for the heterozygous THBDN p.Cys537Stop variant and +/+ 
for reference sequence. Plasma thrombomodulin (TM) concentrations are 
indicated beneath each pedigree symbol. B. A representative thrombin 
generation curve from case II.2 in re-calcified plasma collected into 0.106 mM 
trisodium citrate, following activation with 1 pM tissue factor. The gray shading 
represents the limits of thrombin generation curves observed in 20 healthy 
controls. C-D. Plasma endogenous thrombin potential (ETP) peak thrombin 
concentration from cases I.1 and II.1 (n=10) with thrombomodulin-associated 
coagulopathy (TM-AC) and in plasma from 20 healthy controls in the absence 
or presence of recombinant C-terminal truncated human TM (sTM; 250-2500 
ng/ml; high-TM model plasma).  E-F. ETP in plasma from cases I.1 and II.1 
and in high-TM model plasma containing 500 ng/ml sTM and either 25-100 
µg/mL recombinant activated FVII (rFVIIa) or 0.25-0.75 U/mL activated 
prothrombin complex concentrate (aPCC). Statistical comparisons are 
between ETP values in the presence of the stated concentration of bypassing 
agent vs ETP in the corresponding sample with no added bypassing agent. 
The gray boxes indicates the range of ETP observed in 20 healthy control 
plasmas without addition of sTM. Data are means ± SEM; ** p ≤0.01, NS = 
not significant. 
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Figure 2: Plasma and whole blood fibrinolysis 
A-C. Turbidity measured in triplicate at 405 nm in plasma from 
thrombomodulin-associated coagulopathy (TM-AC) cases I.1 and II.1 (n=6), 
high-TM model plasma containing 500 ng/ml recombinant C-terminal 
truncated human TM (sTM; n=3), or control plasma without added sTM (n=3) 
diluted 30:70 in TBST buffer (10 mM Tris, 140 nM NaCl, 0.01% Tween-20, 
pH7.4) containing 16 mM phospholipids. Clotting was initiated with 0.1 U/ml 
thrombin and 10.6 mM CaCl2 in the presence of 300 pM recombinant human 
tissue plasminogen activator. The curves represent mean turbidity with no 
carboxypeptidase inhibitor (no CPI), with 65 µg/ml MA-T12D11 or 25 µg/ml 
PTCI. D. Time to 50% clot lysis in the TM-AC (n=6), high-TM model (n=3) and 
control (n=3) plasma samples in the absence or presence of 65 µg/ml MA-
T12D11 or 25 µg/ml PTCI. E. Representative ROTEM viscoelastometry traces 
following clot formation with the EXTEM reagent in whole blood from a healthy 
control and from TM-AC case II.2. Traces are shown in the absence and 
presence of 5 µg/ml PTCI. F. Time to 90% clot lysis in TM-AC (n=6), high-TM 
model (n=3) and healthy control (n=20) blood in the absence or presence of 
1-10 µg/ml PTCI. G-H. Time to 90% clot lysis in high TM-model blood 
samples in the absence or presence of 25-100 µg/ml recombinant activated 
FVII (rFVIIa) or 0.25-0.75 U/ml activated prothrombin complex concentrate 
(aPCC) n=3). Data are means ± SEM; ** p ≤0.01, NS = not significant. 
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Supplementary table S1: Coagulation laboratory test results levels from the study cases I.1 and II.2 with thrombomodulin-associated coagulopathy.  
!
 Reference range I.1 II.2 
PT (s) 9.5 -12.0 10.3 10.7 
APTT (s) 23.0 - 32.0 25.3 26.3 
Clauss fibrinogen (g/l) 1.5 - 4.0 2.1 2.06 
VWF:Ag (IU/ml) 0.5 - 2.0 1.12 1.05 
VWF:RCo (IU/ml) 0.5 -2.0 0.85 0.93 
FIX:C (IU/ml) 0.5 - 2.0 0.98 1.06 
FVIII:C (IU/ml) 0.5 - 2.0 1.44 1.08 
FXI:C (IU/ml) 0.7 - 2.0 1.02 0.94 
Free protein S antigen (IU/ml) 0.64 -1.31 1.19 1.55 
Protein C activity (IU/ml) 0.7 - 1.4 1.06 0.97 
Factor V Leiden genotype - Reference sequence Reference sequence 
Plasminogen activity (%) 75 - 140 122 105 
Endogenous thrombin potential (nM/min) 1092.4 - 2077.4 81.9 ± 10.3* 428.2 ± 20.1* 
Peak thrombin concentration (nM) 101.7 - 445.7 15.4 ± 2.6* 100.8 ± 6.7* 
Lag time (s) 2.8 - 6.8 4.1 ± 0.5* 4.3 ± 0* 
Time to peak thrombin (s) 4.5 - 11.6 9.3 ± 0.2* 6.4 ± 0.2* 
ROTEM clot time (s) 62.4 - 70.2 67.3 ± 1.1* 65.5 ± 0.9* 
ROTEM alpha angle (°) 70.2 - 75.0 72.6 ± 0.3* 71.0 ± 0.4* 
ROTEM maximum clot firmness (mm) 48.4 - 61.1 58.1 ± 1.0* 60.25 ± 0.6* 
ROTEM time to 90% clot lysis (min) 22.7 - 36.3 58.8 ± 4.3* 55.1 ± 2.1* 
ROTEM % clot lysis at 30 minutes (LY 30) 1.8 - 8.5 93.5 ± 2.1* 97.5 ± 1.0* 
ROTEM % clot lysis at 60 minutes (LY 60) 1.8 - 6.2 4.5 ± 0.84* 7.0 ± 1.4* 
Analyses were performed using a CS-21000i coagulometer (Sysmex AG, Horgen, Switzerland) using Seimens reagents, a Fluoroscan Ascent fluorimeter (Thermo-Fischer, 
Basingstoke, UK) and a ROTEM rotational viscoelastometer (Haemonetics, Braintree, MA) according to the manufacturers instructions using venous blood samples collected 
into 0.106 mM trisodium citrate. Coagulation assays for FVIII:C, FXI:C and FXI: C were one-stage APTT based assays. VWF:Ag was measured using the VWFAg 
immunoturbidimetric reagent and VWF:Rco using the BC VWF RCof activity kit. Protein C activity was determined using the Chromogenic PC activity kit and free protein S 
antigen with the Innovance free protein S kit. Plasminogen activity was determined using the Berichrom Plasminogen kit. *indicates mean± SEM for the results of replicate 
measurements (n=4-10) for patient (n=4-10) and model samples or healthy controls (n=20). 
